22 December 2017 - - US-based biopharmaceutical company vTv Therapeutics Inc.'s (NASDAQ: VTVT) vTv Therapeutics LLC has entered into a global licensing agreement with Reneo Pharmaceuticals, a privately-held biotechnology company focused on developing treatments for orphan diseases, the company said.

The agreement grants Reneo Pharmaceuticals exclusive worldwide rights to research, develop and commercialize vTv Therapeutics' selective peroxisome proliferator-activated receptor delta (PPAR-delta) program.

Under the terms of the agreement, vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialisation milestones as well as royalties on sales of approved products. vTv Therapeutics will also receive shares of Reneo Pharmaceuticals' common stock.

HPP593, a functionally selective PPAR-delta agonist, has demonstrated a lowering of low-density lipoprotein cholesterol and triglycerides in animal models and humans, with a significant increase in high-density lipoprotein cholesterol. HPP593 has also demonstrated an anti-diabetic effect in several animal models of type 2 diabetes. Phase 1 studies have shown HPP593 to be well tolerated.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.

The company has a pipeline of clinical drug candidates led by programmes for the treatment of Alzheimer's disease and diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.